Yipinhong subsidiary gains NMPA approval for polyethylene glycol oral solution in China
Yipinhong Pharmaceutical Co., Ltd. announced on September 20 that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical, received a Drug Registration Certificate from China's National Medical Products Administration for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution. The drug, classified as a Class 3 chemical drug, is indicated for chronic constipation and fecal impaction. The approval allows the company to manufacture and market the product domestically, enriching its chronic disease medication pipeline.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- China's consistency evaluation system is a genuine regulatory achievement that didn't exist a decade ago.
- Chronic constipation is a real public health burden, especially for the elderly.
- Yipinhong and 3G Pharma are the same corporate entity.
- Domestic pharmaceutical self-sufficiency has strategic value for China.
Points of contention
- Eastern Agent sees this approval as a major step in challenging Western pharmaceutical hegemony, while Neutral Agent views it as a routine generic approval in a saturated market.
- Eastern Agent argues the approval funds future innovation, while Neutral Agent says there's no evidence of reinvestment into novel drugs.
- Neutral Agent focuses on market saturation and price compression as negatives, while Eastern Agent sees lower prices for patients as a public health win.
- Eastern Agent frames the approval as a geopolitical victory for the multipolar world order, while Neutral Agent calls this narrative inflation over a mundane event.
Blind spots
- Neither side provided concrete data on how many patients this drug will actually reach or the price difference versus existing generics.
- The debate overlooked whether Yipinhong has a manufacturing cost advantage or any differentiated formulation.
- Both agents ignored the potential opportunity cost of regulatory resources spent on a fourth generic instead of drugs for unmet needs like rare diseases or pediatric care.
- The geopolitical framing by Eastern Agent lacks evidence that this specific approval reduces dependency on foreign drugs, since multiple domestic generics already exist.
WorldAttention’s read
This debate shows a clear divide between a strategic, sovereignty-focused view and a market-driven, data-focused analysis. Both sides agree that China's consistency evaluation system is a real achievement, but they clash on whether this specific approval matters. Eastern Agent sees it as a brick in the wall of pharmaceutical self-reliance, while Neutral Agent sees it as a routine generic in a crowded market with thin margins. The blind spots are significant: neither side provided hard numbers on patient access, pricing, or reinvestment into innovation. The truth likely lies in the middle—this is a modest regulatory milestone that validates China's improved drug approval system, but it's not a geopolitical breakthrough or a game-changer for public health. The real value is in the system itself, not this particular drug.
Reporting timeline
Yipinhong Subsidiary Gets China Drug Approval for Polyethylene Glycol Oral Solution
Yipinhong (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical, has received a Drug Registration Certificate from China's National Medical Products Administration for a compound polyethylene glycol (3350) electrolyte oral solution. The drug, classified as a Category 3 chemical drug, is deemed to have passed consistency evaluation with the original brand. Its approved indications are the treatment of chronic constipation and fecal impaction. According to data from Menet, the sales scale of polyethylene glycol in Chinese urban and county public hospitals was approximately 221 million yuan in 2025. This approval qualifies the company to market the drug domestically, which the company states will further enrich its product pipeline and enhance its competitiveness in the chronic disease drug market.
Read sourceYipinhong Subsidiary Receives Drug Registration Certificate for Compound Polyethylene Glycol Oral Solution
On September 20, Yipinhong Pharmaceutical Co., Ltd. announced that its subsidiary has received the Drug Registration Certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution, approved by China's National Medical Products Administration. The approval qualifies the company to sell this drug specification in the domestic market, enriching its product pipeline and enhancing competitiveness in the chronic disease medication sector. The drug is indicated for treating constipation and fecal impaction. According to data from Menet, polyethylene glycol sales in China's urban and county hospitals are projected to reach a certain level by 2025. The report also notes that by mid-2026, Yipinhong achieved revenue of RMB 492 million and net profit attributable to shareholders of the parent company of RMB 485 million. The source is Caizhong She via East Money.
Yipinhong Subsidiary Receives Drug Registration Certificate for Polyethylene Glycol Oral Solution
Yipinhong announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has recently received a Drug Registration Certificate from the National Medical Products Administration (NMPA) for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution. The approved specification is 25ml per bag, with the drug approval number Guoyao Zhunzi H20265982. The product is classified as a Chemical Drug Class 3 and is deemed to have passed consistency evaluation with the reference listed drug. This regulatory approval allows the subsidiary to manufacture and market the product in China.
Read sourceShow 4 older updatesHide older updates
Yipinhong Subsidiary Gets Drug Registration for Polyethylene Glycol Oral Solution
Yipinhong (300723) announced on September 20 that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution from China's National Medical Products Administration. According to the approved package insert, the drug is indicated for the treatment of chronic constipation and fecal impaction. The company applied for registration as a Class 3 chemical drug, which is deemed to have passed consistency evaluation. The announcement was reported by People's Finance News and sourced from stockstar_securities_news.
Read source3G Pharma Subsidiary Gets Registration Certificate for Polyethylene Glycol Oral Solution
3G Pharma (300723.SZ) announced on September 20 that its wholly-owned subsidiary, Guangzhou 3G Pharma Co., Ltd., has received a Drug Registration Certificate from China's National Medical Products Administration for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution. According to the approved package insert, the oral solution is indicated for the treatment of chronic constipation and fecal impaction. The active ingredient, polyethylene glycol 3350, produces a laxative effect through osmotic action in the intestine, with the onset of action varying depending on the severity of the condition. The electrolyte components in the formulation help maintain sodium, potassium, and water balance in the body.
Read sourceYipinhong Subsidiary Gets Drug Registration Certificate for Compound Polyethylene Glycol Oral Solution
On September 20, Yipinhong Pharmaceutical Co., Ltd. announced that its subsidiary received a Drug Registration Certificate from China's National Medical Products Administration for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution. According to the approved package insert, the drug is indicated for the treatment of chronic constipation and fecal impaction. Yipinhong stated that obtaining this certificate qualifies the company to sell this specification of the drug in the domestic market, further enriching its product pipeline and categories, and strengthening its competitiveness in the chronic disease medication segment. The announcement was reported by Beijing Business Today via East Money.
Read sourceYipinhong Receives NMPA Approval for Compound Polyethylene Glycol Electrolyte Oral Solution
Yipinhong Pharmaceutical Co., Ltd. announced on September 20 that it has received a Drug Registration Certificate from China's National Medical Products Administration (NMPA) for its Compound Polyethylene Glycol (3350) Electrolyte Oral Solution. According to the approved package insert, the drug is indicated for the treatment of chronic constipation and fecal impaction. The company registered the product as a Class 3 chemical drug, which is deemed to have passed consistency evaluation. The news was reported by Securities Times Network and published on East Money's company reports section.
Read source